Brief: Enzychem Lifesciences Initiates Phase 2 Study For Ec-18 In Preventing Acute Respiratory Distress Syndrome (Ards) Due To Novel Coronavirus Pneumonia
14/05/2020 19:49
May 14 (Reuters) - Enzychem Lifesciences Corp 183490.KQ :
* ENZYCHEM LIFESCIENCES INITIATES PHASE 2 STUDY FOR EC-18 IN
PREVENTING ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) DUE TO
NOVEL CORONAVIRUS PNEUMONIA
* ENZYCHEM LIFESCIENCES - IN CLINICAL STUDIES TO DATE, EC-18
OBSERVED TO BE GENERALLY SAFE & WELL TOLERATED WITH NO
DRUG-RELATED SERIOUS ADVERSE EVENTS
Source text for Eikon: ID:nPn7cj0Pja
Further company coverage: 183490.KQ
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Enzychem Lifesciences
See all newsBrief: Enzychem Lifesciences To Divest 8 Billion Won Worth Of Own Shares
Brief: Enzychem Lifesciences Announces Completion Of Clinical Study Report (Csr) For Phase 2 Study Of Ec-18 In Chemoradiation-Induced Oral Mucositis
South Korea's Enzychem to make Indian drugmaker Cadila's COVID-19 shot (updated)
Brief: Cadila Healthcare Inks Deal With South Korea's Enzychem For Plasmid DNA Vaccine
South Korea's Enzychem to make Indian drugmaker Cadila's COVID-19 shot